| 1. Rabinowitz M, Seneci P, Rossi T, Dal Cin M, Deal M, Terstappen G.. (2000) Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands., 10 (10): [PMID:10843203] [10.1016/s0960-894x(00)00104-9] |
| 2. McCluskey A, Sim AT, Sakoff JA.. (2002) Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies., 45 (6): [PMID:11881984] [10.1021/jm010066k] |
| 3. Koch K, Newborg MF, Hanson DC, Cooper K, Shepard RM, Biehl ML, Biggers MS, Ramchandani M, Schulte G, Snyder JR.. (1995) The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant., 38 (8): [PMID:7537331] [10.1021/jm00008a001] |
| 4. Wagner R, Rhoades TA, Or YS, Lane BC, Hsieh G, Mollison KW, Luly JR.. (1998) 32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency., 41 (11): [PMID:9599228] [10.1021/jm960066y] |
| 5. Teague SJ, Stocks MJ. (1993) The affinity of the excised binding domain of FK-506 for the immunophilin FKBP12., 3 (10): [10.1016/S0960-894X(01)80992-6] |
| 6. Armstrong HM, Wong F, Holmes MA, Sinclair PJ, Goulet MT, Dumont FJ, Staruch MJ, Koprak S, Peterson LB, Rosa R, Wilusz MB, Wiederrecht GJ, Cryan JG, Wyvratt MJ, Parsons WH.. (1999) Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity., 9 (14): [PMID:10450987] [10.1016/s0960-894x(99)00336-4] |
| 7. Goulet MT, McAlpine SR, Staruch MJ, Koprak S, Dumont FJ, Cryan JG, Wiederrecht GJ, Rosa R, Wilusz MB, Peterson LB, Wyvratt MJ, Parsons WH.. (1998) C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential., 8 (16): [PMID:9873523] [10.1016/s0960-894x(98)00397-7] |
| 8. Hersperger R, Schuler W, Zenke G.. (1999) Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin., 9 (2): [PMID:10021934] [10.1016/s0960-894x(98)00702-1] |
| 9. Teague SJ, Cooper ME, Stocks MJ. (1995) Synthesis of FK506-Cyclosporin hybrid macrocycles, 5 (20): [10.1016/0960-894X(95)00404-H] |
| 10. Ishchenko AV, Shakhnovich EI.. (2002) SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions., 45 (13): [PMID:12061879] [10.1021/jm0105833] |
| 11. Becker JW, Rotonda J, Cryan JG, Martin M, Parsons WH, Sinclair PJ, Wiederrecht G, Wong F.. (1999) 32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein., 42 (15): [PMID:10425089] [10.1021/jm9806042] |
| 12. Yamashita DS, Oh H, Yen H, Bossard MJ, Brandt M, Levy MA, Newman-Tarr T, Badger A, Luengo JI, Holt DA. (1994) Design, synthesis and evaluation of dual domain FKBP ligands, 4 (2): [10.1016/S0960-894X(01)80137-2] |
| 13. Christner C, Wyrwa R, Marsch S, Küllertz G, Thiericke R, Grabley S, Schumann D, Fischer G.. (1999) Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties., 42 (18): [PMID:10479292] [10.1021/jm991038t] |
| 14. Wiedeman PE, Fesik SW, Petros AM, Nettesheim DG, Mollison KW, Lane BC, Or YS, Luly JR.. (1999) Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12., 42 (21): [PMID:10543889] [10.1021/jm980252z] |
| 15. Hamilton GS, Steiner JP.. (1998) Immunophilins: beyond immunosuppression., 41 (26): [PMID:9857082] [10.1021/jm980307x] |
| 16. Organ HM, Holmes MA, Pisano JM, Staruch MJ, Wyvratt MJ, Dumont FJ, Sinclair PJ. (1993) Novel derivatives at the C21 position of the FK-506 macrocycle, 3 (4): [10.1016/S0960-894X(01)81248-8] |
| 17. Goulet MT, Hodkey DW, Staruch MJ, Dumont FJ, Cryan JG, Parsons WH, Wyvratt MJ. (1994) Alkyl ether analogs of the FK-506 related, immunosuppressive macrolide L-683,590 (ascomycin), 4 (7): [10.1016/S0960-894X(01)80264-X] |
| 18. Goulet MT, Hodkey DW, Staruch MJ, Dumont FJ, Lin S, Hung SH, Siekierka JJ, Wyvratt MJ. (1994) Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-O-desmethyl ascomycin), 4 (7): [10.1016/S0960-894X(01)80265-1] |
| 19. Kawai M, Gunawardana IW, Mollison KW, Hsieh GC, Lane BC, Luly JR.. (1998) Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative., 8 (8): [PMID:9871515] [10.1016/s0960-894x(98)00145-0] |
| 20. Itzhak Y, Kalir A, Weissman BA, Cohen S.. (1981) New analgesic drugs derived from phencyclidine., 24 (5): [PMID:7241506] [10.1021/jm00137a004] |
| 21. Hersperger R, Buchheit KH, Cammisuli S, Enz A, Lohse O, Ponelle M, Schuler W, Schweitzer A, Walker C, Zehender H, Zenke G, Zimmerlin AG, Zollinger M, Mazzoni L, Fozard JR.. (2004) A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma., 47 (20): [PMID:15369399] [10.1021/jm031101l] |
| 22. Wang YH, Li Y, Li YH, Yang SL, Yang L.. (2005) Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism., 15 (18): [PMID:15990295] [10.1016/j.bmcl.2005.06.015] |
| 23. Zhao L, Huang W, Liu H, Wang L, Zhong W, Xiao J, Hu Y, Li S.. (2006) FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5,5-dimethyl-2-(4-thiazolidine)carboxylates., 49 (14): [PMID:16821768] [10.1021/jm0502384] |
| 24. Xie C, Koshino H, Esumi Y, Onose J, Yoshikawa K, Abe N.. (2006) Vialinin B, a novel potent inhibitor of TNF-alpha production, isolated from an edible mushroom, Thelephora vialis., 16 (20): [PMID:16901696] [10.1016/j.bmcl.2006.07.068] |
| 25. Stebbins JL, Zhang Z, Chen J, Wu B, Emdadi A, Williams ME, Cashman J, Pellecchia M.. (2007) Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors., 50 (26): [PMID:18038971] [10.1021/jm0707424] |
| 26. Moda TL, Montanari CA, Andricopulo AD.. (2007) Hologram QSAR model for the prediction of human oral bioavailability., 15 (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060] |
| 27. Fujimoto H, Nakamura E, Kim YP, Okuyama E, Ishibashi M, Sassa T.. (2001) Immunomodulatory constituents from an Ascomycete, Eupenicillium crustaceum, and revised absolute structure of macrophorin D., 64 (9): [PMID:11575965] [10.1021/np010152n] |
| 28. Steinbach WJ, Cramer RA, Perfect BZ, Henn C, Nielsen K, Heitman J, Perfect JR.. (2007) Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus., 51 (8): [PMID:17502415] [10.1128/aac.01394-06] |
| 29. Fujimoto H, Sumino M, Okuyama E, Ishibashi M.. (2004) Immunomodulatory constituents from an Ascomycete, Chaetomium seminudum., 67 (1): [PMID:14738397] [10.1021/np0302201] |
| 30. Onyewu C, Eads E, Schell WA, Perfect JR, Ullmann Y, Kaufman G, Horwitz BA, Berdicevsky I, Heitman J.. (2007) Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model., 51 (10): [PMID:17664323] [10.1128/aac.00492-07] |
| 31. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.. (2009) Physicochemical determinants of human renal clearance., 52 (15): [PMID:19445515] [10.1021/jm900403j] |
| 32. Zhuang D, Smedema M, Lemonte A, Book BK, Pescovitz MD, Wheat LJ.. (2008) Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay., 52 (2): [PMID:18025114] [10.1128/aac.01096-07] |
| 33. Varma MV, Obach RS, Rotter C, Miller HR, Chang G, Steyn SJ, El-Kattan A, Troutman MD.. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination., 53 (3): [PMID:20070106] [10.1021/jm901371v] |
| 34. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y.. (2007) Splicing factor SF3b as a target of the antitumor natural product pladienolide., 3 (9): [PMID:17643112] [10.1038/nchembio.2007.16] |
| 35. PubChem BioAssay data set, |
| 36. PubChem BioAssay data set, |
| 37. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 38. Fortwendel JR, Juvvadi PR, Pinchai N, Perfect BZ, Alspaugh JA, Perfect JR, Steinbach WJ.. (2009) Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus., 53 (2): [PMID:19015336] [10.1128/aac.01154-08] |
| 39. Lamping E, Ranchod A, Nakamura K, Tyndall JD, Niimi K, Holmes AR, Niimi M, Cannon RD.. (2009) Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei., 53 (2): [PMID:19015352] [10.1128/aac.01095-08] |
| 40. Dannaoui E, Schwarz P, Lortholary O.. (2009) In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes., 53 (8): [PMID:19451295] [10.1128/aac.00184-09] |
| 41. da Silva FR, Tessis AC, Ferreira PF, Rangel LP, Garcia-Gomes AS, Pereira FR, Berlinck RG, Muricy G, Ferreira-Pereira A.. (2011) Oroidin inhibits the activity of the multidrug resistance target Pdr5p from yeast plasma membranes., 74 (2): [PMID:21207971] [10.1021/np1006247] |
| 42. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A.. (2010) Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species., 23 (1): [PMID:20014752] [10.1021/tx900326k] |
| 43. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 44. PubChem BioAssay data set, |
| 45. Kiang TK, Ensom MH, Chang TK.. (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions., 106 (1): [PMID:15781124] [10.1016/j.pharmthera.2004.10.013] |
| 46. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, |
| 47. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W.. (2011) FDA-approved drug labeling for the study of drug-induced liver injury., 16 (15-16): [PMID:21624500] [10.1016/j.drudis.2011.05.007] |
| 48. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 49. Ye YQ, Onose J, Abe N, Koshino H, Takahashi S.. (2012) Design and synthesis of a vialinin A analog with a potent inhibitory activity of TNF-α production and its transformation into a couple of bioprobes., 22 (7): [PMID:22410084] [10.1016/j.bmcl.2012.02.034] |
| 50. Schuetz EG, Beck WT, Schuetz JD.. (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells., 49 (1): [PMID:8632764] |
| 51. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T.. (1993) Human P-glycoprotein transports cyclosporin A and FK506., 268 (1): [PMID:7681059] [10.1016/s0021-9258(18)53221-x] |
| 52. Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K.. (2001) Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation., 69 (1): [PMID:11371998] [10.1067/mcp.2001.115142] |
| 53. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, Tsuji A.. (1999) P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice., 16 (1): [PMID:10468022] [10.1023/a:1018993312773] |
| 54. Fehrenbach T, Cui Y, Faulstich H, Keppler D.. (2003) Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins., 368 (1): [PMID:14530907] [10.1007/s00210-003-0814-4] |
| 55. Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, Yokogawa K, Miyamoto KI, Hasegawa T.. (2000) Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo., 27 (1): [PMID:10901387] [10.1046/j.1440-1681.2000.03308.x] |
| 56. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G.. (2004) Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo., 21 (1): [PMID:15180340] [10.1023/b:pham.0000026434.82855.69] |
| 57. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.. (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies., 59 (1): [PMID:10463589] |
| 58. Martina MR, Tenori E, Bizzarri M, Menichetti S, Caminati G, Procacci P.. (2013) The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a New class of nanomolar FKBP12 ligands., 56 (3): [PMID:23301792] [10.1021/jm3015052] |
| 59. PubChem BioAssay data set, |
| 60. Wang Y, Kirschner A, Fabian AK, Gopalakrishnan R, Kress C, Hoogeland B, Koch U, Kozany C, Bracher A, Hausch F.. (2013) Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control., 56 (10): [PMID:23647266] [10.1021/jm400087k] |
| 61. Okada K, Ye YQ, Taniguchi K, Yoshida A, Akiyama T, Yoshioka Y, Onose J, Koshino H, Takahashi S, Yajima A, Abe N, Yajima S.. (2013) Vialinin A is a ubiquitin-specific peptidase inhibitor., 23 (15): [PMID:23791076] [10.1016/j.bmcl.2013.05.093] |
| 62. Unpublished dataset, |
| 63. Harikishore A, Leow ML, Niang M, Rajan S, Pasunooti KK, Preiser PR, Liu X, Yoon HS.. (2013) Adamantyl derivative as a potent inhibitor of Plasmodium FK506 binding protein 35., 4 (11): [PMID:24900611] [10.1021/ml400306r] |
| 64. Giordanetto F, Kihlberg J.. (2014) Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?, 57 (2): [PMID:24044773] [10.1021/jm400887j] |
| 65. Moss SJ, Stanley-Smith AE, Schell U, Coates NJ, Foster TA, Gaisser S, Gregory MA, Martin CJ, Nur-e-Alam M, Piraee M, Radzom M, Suthar D, Thexton DG, Warneck TD, Zhang M, Wilkinson B. (2013) Novel FK506 and FK520 analogues via mutasynthesis: mutasynthon scope and product characteristics, 4 (2): [10.1039/C2MD20266B] |
| 66. Biour M, Ben Salem C, Chazouillères O, Grangé JD, Serfaty L, Poupon R.. (2004) [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]., 28 (8-9): [PMID:15646539] [10.1016/s0399-8320(04)95062-2] |
| 67. Gibbs AC.. (2014) Elements and modulation of functional dynamics., 57 (19): [PMID:24913411] [10.1021/jm500325k] |
| 68. Laverdière I, Caron P, Harvey M, Lévesque É, Guillemette C.. (2011) In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4., 39 (7): [PMID:21487055] [10.1124/dmd.111.039040] |
| 69. Lin X, Skolnik S, Chen X, Wang J.. (2011) Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model., 39 (2): [PMID:21051535] [10.1124/dmd.110.034629] |
| 70. Amundsen R, Åsberg A, Ohm IK, Christensen H.. (2012) Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro., 40 (4): [PMID:22205779] [10.1124/dmd.111.043018] |
| 71. Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, Xia M.. (2011) Identification of clinically used drugs that activate pregnane X receptors., 39 (1): [PMID:20966043] [10.1124/dmd.110.035105] |
| 72. Drug metabolism data, |
| 73. Tobe M, Tsuboi K, Hasegawa F, Fujiwara N, Inoue Y, Isobe M, Isobe Y.. (2016) Synthesis and biological evaluation of novel orally available 1-phenyl-6-aminouracils containing dimethyldihydrobenzofuranol structure for the treatment of allergic skin diseases., 26 (4): [PMID:26786694] [10.1016/j.bmcl.2016.01.019] |
| 74. Gaali S, Feng X, Hähle A, Sippel C, Bracher A, Hausch F.. (2016) Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51., 59 (6): [PMID:26954324] [10.1021/acs.jmedchem.5b01355] |
| 75. DrugMatrix, [10.6019/CHEMBL3885881] |
| 76. Nambu M, Covel JA, Kapoor M, Li X, Moloney MK, Numa MM, Soltow QA, Trzoss M, Webb P, Webb RR, Mutz M.. (2017) A calcineurin antifungal strategy with analogs of FK506., 27 (11): [PMID:28412204] [10.1016/j.bmcl.2017.04.004] |
| 77. Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Afshari CA, Hamadeh HK.. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development., 136 (1): [PMID:23956101] [10.1093/toxsci/kft176] |
| 78. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W.. (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans., 21 (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015] |
| 79. Luo M, Cui Z, Huang H, Song X, Sun A, Dang Y, Lu L, Ju J.. (2017) Amino Acid Conjugated Anthraquinones from the Marine-Derived Fungus Penicillium sp. SCSIO sof101., 80 (5): [PMID:28509552] [10.1021/acs.jnatprod.7b00269] |
| 80. Liu N, Tu J, Dong G, Wang Y, Sheng C.. (2018) Emerging New Targets for the Treatment of Resistant Fungal Infections., 61 (13): [PMID:29294275] [10.1021/acs.jmedchem.7b01413] |
| 81. Zeng T, Wu XY, Yang SX, Lai WC, Shi SD, Zou Q, Liu Y, Li LM.. (2017) Monoterpenoid Indole Alkaloids from Kopsia officinalis and the Immunosuppressive Activity of Rhazinilam., 80 (4): [PMID:28218521] [10.1021/acs.jnatprod.6b00697] |
| 82. Unpublished dataset, |
| 83. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek. (2020) Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection, [10.21203/rs.3.rs-23951/v1] |
| 84. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson. (2020) Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2, [10.1101/2020.04.21.054387] |
| 85. Wang Y, Peiffer BJ, Su Q, Liu JO.. (2019) One-step Heck Reaction Generates Nonimmunosuppressive FK506 Analogs for Pharmacological BMP Activation., 10 (9): [PMID:31531197] [10.1021/acsmedchemlett.9b00144] |
| 86. Beom JY, Jung JA, Lee KT, Hwangbo A, Song MC, Lee Y, Lee SJ, Oh JH, Ha SJ, Nam SJ, Cheong E, Bahn YS, Yoon YJ.. (2019) Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity., 82 (8): [PMID:31321978] [10.1021/acs.jnatprod.9b00144] |
| 87. (2018) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies, |
| 88. Nakajima Y, Aoyama N, Takahashi F, Sasaki H, Hatanaka K, Moritomo A, Inami M, Ito M, Nakamura K, Nakamori F, Inoue T, Shirakami S.. (2016) Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3., 24 (19): [PMID:27544589] [10.1016/j.bmc.2016.08.007] |
| 89. Rana P, Will Y, Nadanaciva S, Jones LH.. (2016) Development of a cell viability assay to assess drug metabolite structure-toxicity relationships., 26 (16): [PMID:27397500] [10.1016/j.bmcl.2016.06.088] |
| 90. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 91. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 92. Qi C,Tan X,Shi Z,Feng H,Sun L,Hu Z,Chen G,Zhang Y. (2020) Discovery of an Oxepine-Containing Diketopiperazine Derivative Active against Concanavalin A-Induced Hepatitis., 83 (9.0): [PMID:32897070] [10.1021/acs.jnatprod.0c00558] |
| 93. Gizińska M,Staniszewska A,Kazek M,Koronkiewicz M,Kuryk Ł,Milner-Krawczyk M,Baran J,Borowiecki P,Staniszewska M. (2020) Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella., 30 (23.0): [PMID:32931913] [10.1016/j.bmcl.2020.127545] |
| 94. Atack TC,Raymond DD,Blomquist CA,Pasaje CF,McCarren PR,Moroco J,Befekadu HB,Robinson FP,Pal D,Esherick LY,Ianari A,Niles JC,Sellers WR. (2020) Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35., 11 (11): [PMID:33209191] [10.1021/acsmedchemlett.0c00272] |
| 95. Aizpurua JM,Miranda JI,Irastorza A,Torres E,Eceiza M,Sagartzazu-Aizpurua M,Ferrón P,Aldanondo G,Lasa-Fernández H,Marco-Moreno P,Dadie N,López de Munain A,Vallejo-Illarramendi A. (2021) Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress., 213 [PMID:33493827] [10.1016/j.ejmech.2021.113160] |
| 96. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 97. Jung JA, Lee HJ, Song MC, Hwangbo A, Beom JY, Lee SJ, Park DJ, Oh JH, Ha SJ, Cheong E, Yoon YJ.. (2021) Biosynthesis of Nonimmunosuppressive ProlylFK506 Analogues with Neurite Outgrowth and Synaptogenic Activity., 84 (2.0): [PMID:33534559] [10.1021/acs.jnatprod.0c00767] |
| 98. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G.. (2022) Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators., 237 [PMID:35483322] [10.1016/j.ejmech.2022.114346] |
| 99. Sánchez-Morales A, Biçer A, Panagiotopoulos V, Crecente-Garcia S, Benaiges C, Bayod S, Luís Hernández J, Busqué F, Matsoukas MT, Pérez-Riba M, Alibés R.. (2022) Design and synthesis of a novel non peptide CN-NFATc signaling inhibitor for tumor suppression in triple negative breast cancer., 238 [PMID:35700596] [10.1016/j.ejmech.2022.114514] |
| 100. Wuelfing WP, El Marrouni A, Lipert MP, Daublain P, Kesisoglou F, Converso A, Templeton AC.. (2022) Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery., 65 (3.0): [PMID:35060378] [10.1021/acs.jmedchem.1c01687] |
| 101. Zhang Q, Fan Z, Zhang L, You Q, Wang L.. (2021) Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer., 64 (13.0): [PMID:34156850] [10.1021/acs.jmedchem.1c00631] |
| 102. Dunyak BM, Gestwicki JE.. (2016) Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds., 59 (21): [PMID:27409354] [10.1021/acs.jmedchem.6b00411] |
| 103. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
